70710-1159 : Mirabegron 25 mg Oral Tablet, Extended Release


NDC: 70710-1159
Labeler: Zydus Pharmaceuticals (Usa) Inc.
Product Type: Human Prescription Drug
Drug Name:  Mirabegron
Dosage Form: Oral Tablet, Extended Release
Application #: ANDA209488
Rev. Date: 


NDC Package Codes:

  • 70710-1159-1: 100 TABLET, EXTENDED RELEASE IN 1 BOTTLE (70710‑1159‑1)
  • 70710-1159-3: 30 TABLET, EXTENDED RELEASE IN 1 BOTTLE (70710‑1159‑3)
  • 70710-1159-9: 90 TABLET, EXTENDED RELEASE IN 1 BOTTLE (70710‑1159‑9)

Active Ingredients:

  • Mirabegron

Dosage Strength:

  • 25 mg

Pharmaceutical Classes:

  • Adrenergic beta3-Agonists [MoA]
  • Cytochrome P450 2D6 Inhibitors [MoA]
  • Cytochrome P450 3A Inhibitors [MoA]
  • P-Glycoprotein Inhibitors [MoA]
  • beta3-Adrenergic Agonist [EPC]

Related Products:

Based on records with the same trade name.
  • 70710-1160 Mirabegron 50 mg Oral Tablet, Extended Release by Zydus Pharmaceuticals (Usa) Inc.
  • 68180-151 Mirabegron 25 mg Oral Tablet, Film Coated, Extended Release by Lupin Pharmaceuticals, Inc.
  • 68180-152 Mirabegron 50 mg Oral Tablet, Film Coated, Extended Release by Lupin Pharmaceuticals, Inc.
  • 70771-1752 Mirabegron 25 mg Oral Tablet, Extended Release by Zydus Lifesciences Limited
  • 70771-1753 Mirabegron 50 mg Oral Tablet, Extended Release by Zydus Lifesciences Limited

NDC QR Code

Scan the QR code below to easily reference this data in the future:

NDC 70710-1159 QR Code

< Prev: 70710-1158Next: 70710-1160 >




Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.